Company expects topline readout from Phase 3 ALLOHA-2 trial in mid-2028.
TScan plans to initiate Phase 1 studies of TSC-102-A01 and TSC-102-A03 in Q4 2026.
Company expects existing cash to fund operations into Q2 2027.
Analyst coverage
The current average analyst rating on the shares is buy and the breakdown of recommendations is 5 strong buy or buy, 2 hold and no sell or strong sell.
The average consensus recommendation for the biotechnology & medical research peer group is buy.
Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 672.4% above its August 11 closing price of $0.78.
Quarterly results
US biotech firm's Q2 collaboration revenue fell year over year, driven by timing of research activities.
Net loss for Q2 narrowed as R&D and G&A expenses declined.
Company posted Q2 collaboration and license revenue of $1.05 million, compared with a net loss of $30.36 million, loss from operations of $30.49 million, loss per basic share of $0.23, and operating expenses of $31.54 million.
Clinical and manufacturing updates
Company dosed the first patient in pivotal Phase 3 trial, with topline data expected in mid-2028.
Positive initial data from Cohort C of Phase 1 ALLOHA study validated commercial-ready manufacturing process, with about 90% first-pass success rate.
Patients with poor prognostic features in Cohort C showed meaningful clinical benefit from TSC-101.
TCRX•
